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Head and neck cancer
Radiotherapy
Biomarker
OropharynxIntroduction and background: A significant proportion of patients with intermediate and high risk squa-
mous cell cancer of the oropharynx (OPSCC) continue to relapse locally despite radical chemoradiother-
apy (CRT). The toxicity of the current combination of intensified dose per fraction radiotherapy and
platinum based chemotherapy limits further uniform intensification. If a predictive biomarker for out-
comes from CRT can be identified during treatment then individualised and adaptive treatment strategies
may be employed.
Methods/design: The MeRInO study is a prospective observational imaging study of patients with inter-
mediate and high risk, locally advanced OPSCC receiving radical RT or concurrent CRT Patients undergo
diffusion weighted MRI prior to treatment (MRI_1) and during the third week of RT (MRI_2). Apparent
diffusion coefficient (ADC) measurements will be made on each scan for previously specified target
lesions (primary and lymph nodes) and change in ADC calculated. Patients will be followed up and dis-
ease status for each target lesion noted. The primary aim of the MeRInO study is to determine the thresh-
old change in ADC from baseline to week 3 of RT that may identify the sub-group of non-responders
during treatment.
Discussion: The use of DW-MRI as a predictive biomarker during RT for SCC H&N is in its infancy but stud-
ies to date have found that response to treatment may indeed be predicted by comparison of DW-MRI
carried out before and during treatment. However, previous studies have included all sub-sites and bio-
logical sub-types. Establishing ADC thresholds that predict for local failure is an essential step towards
using DW-MRI to improve the therapeutic ratio in treating SCC H&N. This would be done most robustly
in a specific H&N sub-site and in sub-types with similar biological behaviour. The MeRInO study will help
establish these thresholds in OPSCC.
 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction and background
The incidence of oropharyngeal squamous cell cancer (OPSCC)
has increased greatly in the developed world in recent years [1].
Radiotherapy (RT) or chemo-radiotherapy (CRT) is an organ-preserving alternative to surgery with at least equivalent loco-
regional control and disease-free survival (DFS) [2,3].
Smoking and alcohol are well established risk factors. The
recent increase in incidence, however, is attributed to a rise in
Human Papilloma Virus (HPV) driven OPSCC [4]. It has been shown
that these HPV + OPSCC are more responsive to treatments and
patients have better overall survival (OS) rates than their HPV neg-
ative counterparts [5–7]. However, it has also been demonstrated
that smoking remains a significant factor in disease control with
the risk of death increasing directly as a function of tobacco expo-
sure in all OPSCC patients [8]. Ang et al. [7] suggested that the bio-
Table 1
Risk of death in OPSCCs, Ang et al. [7].
Risk category OS at 3 years Demographics
Low risk 93% HPV+, <10 pack years
HPV+, >10 pack years, N0-2a
Intermediate risk 70.8% HPV+, >10 pack years, N2b-3
HPV, <10 pack years
High risk 46.2% HPV, >10 pack years
HPV, <10 pack years, T4
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rendering them less responsive to therapy. He proposed 3 ‘risk
groups’ for OPSCC, using tumour stage, HPV status and smoking
history to classify patients into low, intermediate or high risk of
death, (Table 1). Current strategies in the low risk group focus on
de-escalation of therapy and clinical trials are ongoing [9]. Con-
versely, intensification of treatment should be considered for the
intermediate and high risk groups, which are the focus of the pro-
posed study.
Patients with HPV-OPSCC tend to be older with significant
smoking and/or alcohol history [10], resulting in more co-
morbidities than their HPV + OPSCC counterparts. Uniform treat-
ment intensification of an already morbid treatment across this
group is therefore unattractive. If, however, a predictive biomarker
could be established to select patients who respond poorly to RT,
an individualised treatment intensification strategy could be used
for those who require it.
The role of imaging in early response detection for SCC H&N is
currently ill-defined. Volumetric assessment during RT using CT or
MRI based anatomical imaging has shown conflicting results [11–
17]. PET-CT with FDG and other tracers continues to be investi-
gated. There is some evidence that changes in FDG PET uptake
early during the course of RT correlates with ultimate tumour
response [18–21]. However, difficulties in delineating target vol-
umes using PET-CT during treatment have been reported [22,23].
DW-MRI enables us to detect the Brownian motion of water
molecules in biological tissues [24]. The apparent diffusion co-
efficient (ADC) value is the parameter that is used to quantify
DW-MRI, estimating the diffusion rate of water molecules in tissue.
[25].
MRI is attractive as an imaging biomarker as it is non-invasive
and does not involve additional radiation exposure. It has better
tissue contrast resolution when compared to CT and is the imaging
modality of choice to accurately define the extent of OPSCC
[3,26,27].
The use of DW-MRI as a predictive biomarker during RT for SCC
H&N is in its infancy but studies have found that response to treat-
ment may indeed be predicted by DW-MRI by acquiring images
before and during treatment. It has been suggested that ‘for DW
imaging to be of clinical value, ADC thresholds need to be estab-
lished that can help predict local failure’ [28]. This is the primary
aim of the MeRInO study – to establish the threshold change in
ADC from baseline to week 3 of RT that can differentiate respon-
ders from non-responders to treatment. This may then allow an
individualised and adaptive approach to treatment based on the
biological behaviour of a tumour during RT.Methods/design
Study organisation/funding
The MeRInO study was designed by a multi-disciplinary collab-
oration from The Beatson West of Scotland Cancer Centre, the
Department of Clinical Physics and Bioengineering, NHS Greater
Glasgow and Clyde, and the University of Glasgow. The study spon-
sor is NHS Greater Glasgow and Clyde (Sponsor reference number
GN15ON249). The study received in-house approval by the Clinical
Trials Executive Committee (CTEC) and National Research Ethics
Committee approval (REC number 15/WS/0159). The study is reg-
istered on the publically accessible database Clinicaltrials.gov
(NCT02497573).
Funding for the study is provided by the Beatson Cancer Charity
(Funding application number 14-15-109). Some participating
investigators are already funded or part funded by the Beatson
Cancer Charity and NHS Research Scotland.Study design and patient population
The study is a prospective, longitudinal, single centre, observa-
tional imaging study of patients with intermediate and high risk,
locally advanced OPSCC receiving primary radical RT or concurrent
CRT.
Two DW-MRI scans will be carried out on participants in addi-
tion to all standard procedures. The information gained from the
MRI scans will not be used to change standard treatment. The first
DW-MRI (MRI_1) will be obtained on the same day RT commences.
The second DW-MRI (MRI_2) will be carried out during the third
week of RT treatment.
The DW-MRI scans will be used to measure ADC in each target
lesion (primary and lymph nodes) and to calculate change in ADC
between the 2 scans. After completion of RT, patients will attend
for follow up visits at 3, 6, 12, 18 and 24 months post treatment.
Fig. 1 shows this schematically.
Inclusion criteria:
 Histologically confirmed HPV negative OPSCC or HPV positive
OPSCC and a significant smoking history (>10 pack years).
 Stage III or IVa or IVb disease.
 Scheduled to undergo radical RT or CRT as primary treatment.
 18 years of age or older.
HPV status: As defined by the Scottish HPV reference labora-
tory, multiplex assay on Luminex technology.
Diagnosis and staging will be carried out as per standard regio-
nal guidelines [29].
Exclusion criteria:
 Sub sites other than oropharynx.
 Low risk OPSCC.
 Patients receiving cetuximab-RT.
 Confirmed distal metastatic disease (stage IVc).
 Patients who have undergone primary surgery for SCC H&N.
 Patients who have received induction chemotherapy.
 Patients with contra-indications to MRI scanning (cardiac pace-
maker, surgery within 8 weeks, aneurysm clipped/treated,
metal fragments in eye, previous cranial surgery, any ferrous
metal in the body, pregnancy).Study objectives and end-points
The primary objective of the MeRInO study is to determine the
threshold change in ADC from baseline to week 3 of RT that can dif-
ferentiate responders from non-responders to treatment. This will
be achieved by measuring ADC on MRI_1 and MRI_2 for all target
lesions. Change in ADC (DADC) and % change in ADC (% DADC) will
be calculated for each lesion and recorded.
Loco-regional failures at 24 months post-treatment will be
recorded and pattern of relapse noted. Relapse status for each tar-
get lesion at 24 months post-treatment will be recorded. Progres-
Screening
Intermediate and high risk OPSCC 
Stage III, IVa, IVb 
 (Chemo) radiation as primary treatment 
Patient undergoes DW MRI in addition to 
standard planning procedures for 
radiotherapy 
Patient undergoes DW MRI in week 3 of 
radiotherapy in addition to standard 
image guidance for radiotherapy 
Eligible for DW MRI study & written 
informed consent? 
Patient attends standard follow up visits 
3, 6, 12 , 18 & 24 mths 
Patient commences standard (chemo) 
radiotherapy  
65Gy/30# 
Fig. 1. Trial pathway.
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distal metastases.
Secondary objectives are to assess
– feasibility of measuring ADC at baseline and week 3 of RT,
– time to relapse for each target lesion,
– correlation of DADC with pattern relapse.
Chemoradiotherapy
Patients may receive concurrent CRT or RT alone as definitive
primary treatment.
For RT planning and treatment patients are immobilised with a
custom made thermoplastic mould with 5 point fixation (Klarity
Medical Products, Newark, Ohio). A contrast enhanced planning
scan is obtained on either a Discovery CT590 RT (GE Medical Sys-
tems, Amersham, UK) or a Philips Brilliance Big Bore (Philips Med-
ical Systems B.V, The Netherlands).Target delineation is carried out by the treating oncologist,
using all available clinical and radiological information from diag-
nosis and staging and with reference to international guidelines
[30]. Peer review and approval of the planning target volumes is
mandatory and standard practice in our centre for all H&N cancers.
A treatment plan is created using the EclipseTM planning system
(Varian medical systems, Palo Alto, CA) and approved by the treat-
ing clinician.
All patients receive RT delivered on a Varian Clinac 600 lin-
ear accelerator using Rapid Arc (Varian medical systems, Palo
Alto, CA) volumetric-modulated arc therapy (VMAT) with 6 MV
photons. Gross tumour and the entirety of involved nodal levels
receive 65 Gy/30# over 6 weeks. Prophylactic dose to areas
considered at high risk of occult disease is 54 Gy/30# over
6 weeks.
Cisplatin is delivered at 100 mg/m2 on days 1 and 22 of treat-
ment for those receiving concurrent chemotherapy as per local
protocols [31]. Concurrent cetuximab is not permitted, nor is
16 C Paterson et al. / Clinical and Translational Radiation Oncology 2 (2017) 13–18induction chemotherapy to keep the cohort as homogeneous as
possible.
Diffusion weighted MRI
All MRI images will be acquired on a Signa 1.5T HDxt (GE, Craw-
ley, UK) scanner with patients in a supine position with neutral
neck position. The decision to not employ immobilisation was
taken to enable the use of the neurovascular coil and to facilitate
recruitment and retention of patients to the study. A measurement
from supra-sternal notch to mandible will ensure intra-subject
consistency of head position at repeat scan. The position of the
hard palate will also be checked on the sagittal localiser to verify
axial alignment. A 16 channel neurovascular coil (HNS NV full,
GE, 2012) provides coverage of the H&N area using the head coils,
anterior and posterior neck coils and anterior chest coils.
MRI sequences will be acquired for anatomical identification of
each target region. T1 weighted, T1 weighted fat sat, and T2
weighted fat sat and post-gadolinium contrast images will be
obtained. The diffusion weighted images will be acquired using a
single shot EPI sequence with several b-values between 0 and
1000 s/mm2. The ADC map will be calculated automatically using
inline post-processing (Optima Edition 23, GE, Milwaukee, 2012)
from the acquired b value images using a mono-exponential fit.
All anatomical and DW images will be imported into the Eclip-
seTM treatment planning system (TPS) (Varian medical systems, Palo
Alto, CA). Target lesions will be delineated on each axial slice of the
ADC maps by expert clinical oncologist (CP) and radiologist (IMcC)
with over 10 years experience. The anatomical MR sequences will
be used to aid delineation generally and in particular identification
and exclusion of necrotic areas on the ADC maps. Necrotic/cystic
areas will be excluded from ADC analysis.
Quality assurance (QA)
To verify the accuracy of ADCmeasurement by the scanner soft-
ware, a phantomwill be scanned monthly. The phantom comprises
four vials containing different concentrations of polyvinylpyrroli-
done (PVP) solution and one vial of distilled water. The range of
ADC values covered by the different concentrations of PVP encom-
passes the clinical range of interest [32]. The ADC measurements
will be recorded using the scanner software and the EclipseTM TPS
(Varian medical systems, Palo Alto, CA).
Daily QA is performed on the MRI scanner to check fundamental
parameters of the system.
RT treatment QA features throughout the process. Peer review
of target volumes created by the treating clinician is required prior
to planning. RT plans are produced and checked by two operators
prior to treating clinician review and approval. Daily on-line KV-KV
imaging is carried out prior to treatment to ensure accuracy of set-
up. Our centre is an active participant in several UK multi-centre
RT studies (e.g. recently NIMRAD [33], ART DECO [34]) and there-
fore subject to scrutiny by the NCRI RTQA group as well as meeting
individual study QA requirements.
Clinical follow up
Following completion of RT, patients will attend for evaluation
at 3, 6, 12, 18 and 24 months post treatment. At each visit, disease
status will be recorded. This assessment will be based on clinical
examination and any available imaging as per standard regional
practice [35].
Local control is defined as:
 Absence of any new mass. Static or reduction of residual mass during follow up (FU)P
24 months.
 Histological confirmation of absence (based on surgical resec-
tion, not biopsy due to potential sampling error).
Local failure or relapse/recurrence is defined as:
 Biopsy proven recurrence.
 Development of new mass or serial increase in size of residual
mass during FUP 24 months.Statistical analysis
Sample size
Around 80 OPSCC patients per year are treated in our centre
with RT or CRT. Analysis of a local database found an overall
relapse rate of 30% for intermediate and high risk OPSCC patients
(unpublished work). This is consistent with previously published
outcomes for locally advanced SCC H&N which had loco-regional
failure of 26.7% in our centre [36].
We estimate that recruiting a sample of 80 patients will provide
24 patients who relapse and 56 patients who do not relapse
assuming a 30% relapse rate. A sample of 24 relapsed patients will
differentiate a test sensitivity of >80% from a sensitivity of <60% at
80% power and 10% 1-sided level of statistical significance. It is
expected that there will be 56 patients who do not relapse. This
number of patients will provide 94% power to distinguish a speci-
ficity of <60% from a specificity of >80% (assuming a 5% 1-sided
level of statistical significance). We anticipate sensitivity and
specificity of over 80% as reported by Kim et al. who found that
the normalised ADC values after the first week of treatment had
the highest accuracy to separate complete from partial responders,
with a sensitivity of 86% and a specificity of 83% [37].Primary analysis
The distribution of baseline demographic and clinical character-
istics of patients will be described. We will report the percentage of
patients with measurements of ADC at baseline and week 3 of RT.
The proportion of patients experiencing loco-regional failure and
progression free survival at the end of the study will be reported.
We will determine the sensitivity and specificity (with 95% CIs)
for loco-regional failure of different cut-off values of the change
in ADC from baseline to week 3. A receiver operator characteristic
(ROC) curve will be used to illustrate the performance of change in
ADC as its discrimination threshold is varied.Secondary analyses
We will determine whether the association between change in
ADC and relapse is different for primary and lymph node lesions.
We will employ survival analysis techniques to determine whether
associations between baseline characteristics (for example initial
ADC value, age, or sex), change in ADC value and time to relapse
exist. We will describe factors associated with drop out or discon-
tinuation/ interruption of treatment.
Analyses will use standard statistical significance level of 0.05.Interim data analysis
The feasibility of measuring ADC at baseline and week 3 of RT
will be assessed after the first 40 patients enter the study. The per-
centage of patients where it is feasible to measure ADC for at base-
line and week 3 of RT will be calculated and the study will be
discontinued if this is <50%.
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The need for a predictive biomarker
Historically, prognostic, rather than predictive, information in
the form of the tumour, nodes, metastases (TNM) staging system
has been used to inform therapeutic decision-making in the man-
agement of OPSCC. A standard approach to treatment of locally
advanced disease has resulted in treatment failure in a significant
proportion and perhaps unnecessary toxicity and functional
impairment in others who may have achieved disease control with
less intensive treatment [38].
The identification of a predictive biomarker is the first step
towards an individualised cancer treatment approach and may
allow an improved therapeutic ratio.
DW-MRI and DADC have been shown to correlate with
response to treatment in prospective and retrospective studies in
SCC H&N.
Kim et al. performed DW-MRI before, 1 week into and approx-
imately 2 weeks after CRT in 33 patients. They found that the nor-
malised ADC values after the first week of treatment had the
highest accuracy to separate complete from partial responders
(sensitivity 86%, specificity 83%) [37].
In a similar study, Vandecaveye et al. found that the DADC val-
ues at week 2 and 4 of CRT were significantly correlated with 2-
year LRC and DFS [29]. In patients with recurrence, the DADC at
2 and 4 weeks was significantly lower than in patients with a com-
plete response in both adenopathies and primary tumour [28].
King et al. corroborated these results, reporting that changes in
serial ADC values were associated with treatment response [39].
They calculated that a fall in ADC during treatment identified
patients who developed treatment failure with 90% accuracy.
A further study by King et al. [40] investigated DADC 2 weeks
into CRT. Tumours that responded to treatment displayed a signif-
icantly higher percentage increase in ADC value at 2 weeks com-
pared to those that failed treatment.
These results suggest an insufficient rise in ADC during treat-
ment correlates with a poor response to RT. Less evidence is avail-
able for a threshold rise in ADC that could be used to select non-
responding tumours for treatment intensification with only 2 stud-
ies assessing this [28,40]. Vandecaveye et al. [28] reported a
threshold rise of 14% for primary lesions and 14.61% for lymph
node metastases. The threshold rise to predict local control in pri-
mary lesions was identified as 15.5% in the study by King et al. [40].
These studies have included all H&N sub-sites with no differen-
tiation between biological sub-types. Establishing a threshold rise
in ADC to predict responders from non-responders would be done
most robustly in a specific H&N sub-site and in sub-types with
similar biological behaviour. This study will therefore validate
the use of DW-MRI as a predictive biomarker specifically in the
intermediate and high risk groups of OPSCC. If a discriminatory
threshold rise in ADC can be identified early in treatment to dis-
criminate non-responders an adaptive, dose-escalated radiother-
apy treatment plan could be delivered for the remainder of the
course in a safe but meaningful fashion. This would form the basis
of subsequent clinical trials.Potential future translational studies
All patients that are recruited for the MeRInO study will be
given information about an exploratory biomarker study collecting
blood samples of patients with malignant disease run by the Glas-
gow experimental cancer medicine centre [41]. Furthermore, his-
tology samples taken at the time of diagnosis will be stored by
the Greater Glasgow & Clyde Bio-repository. It is intended thatthe bank of clinical and radiological data that is acquired from
the MeRInO study may be examined in conjunction with these
blood and tissue samples in the future and potential biomarkers
identified.References
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